AN2 Therapeutics, Inc

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing innovative treatments for prevalent retinal diseases. Founded by experienced leaders in ophthalmology, the company aims to address significant unmet needs by creating therapies that ease the burden on patients and caregivers while improving treatment outcomes. The company's lead product, TH103, is a fully humanized recombinant fusion protein designed for intravitreal delivery, demonstrating potential as a best-in-class anti-VEGF agent. With an experienced management team and support from veteran investors, Kalaris is currently evaluating TH103 in a Phase 1 clinical trial for neovascular age-related macular degeneration, with plans to expand its application to other neovascular and exudative retinal diseases. Generated from the website

LIPAC Oncology is a clinical-stage company based in Menlo Park, California, specializing in the development of precision targeted, locally delivered taxane technology for the treatment of various types of cancer, including Bladder Cancer, Upper Tract Urothelial Carcinoma, Stage II III Ovarian Cancer, Intraperitoneal Carcinoma, and Mesothelioma Malignant Pleural Effusion. With a strong focus on addressing areas of significant unmet medical need, LIPAC Oncology's innovative pipeline of products aims to provide life-saving treatment options for cancer patients through breakthrough nano liposome-bound technology, offering localized tumor treatment.Generated from the website

Hexagon Bio, Inc., located in Menlo Park, CA, is a biotechnology company focused on discovering novel medicines for cancer by mining global metagenomes. The company leverages advanced technologies in computation and chemistry to develop next-generation antibody drug conjugate (ADC) payloads, addressing major unmet medical needs. With a diverse and interdisciplinary team of drug hunters, data scientists, biologists, chemists, and engineers, Hexagon Bio is committed to utilizing evolved medicines to enhance patient outcomes. Their innovative approach aims to unlock new therapeutic avenues, revolutionizing cancer treatment. Generated from the website